242
Participants
Start Date
May 9, 2018
Primary Completion Date
June 18, 2019
Study Completion Date
June 18, 2019
Bempedoic acid + Ezetimibe FDC Oral Tablet
Experimental therapy of bempedoic acid 180 mg + ezetimibe 10 mg FDC tablet
Ezetimibe 10 mg Oral Tablet
Ezetimibe 10 mg tablet, overencapsulated for blinding purposes
Placebo Oral Tablet
Placebo tablet, matched for the FDC product for blinding purposes
Placebo oral capsule
Placebo over-encapsulated for blinding purposes
Hampton Roads Center for Clinical Research, Suffolk
FInlay Medical Research, Miami
L-MARC Research Center, Louisville
Clinical Trials Research, Lincoln
Lead Sponsor
Esperion Therapeutics, Inc.
INDUSTRY